Seema Tewari¹*, Vinod Kumar² and Lori Tewari³

¹Assistant Director, Department of Physiology, Advance Neuro and General Hospital, India
²Consultant Neurosurgeon, Advance Neuro and General Hospital, India
³EMO, Advance Neuro and General Hospital, India

*Corresponding Author: Seema Tewari, Assistant Director, Department of Physiology, Advance Neuro and General Hospital, India.

Received: August 22, 2025; Published: September 14, 2025

Abstract

Background: Tissue Plasminogen Activator (tPA) showed a level 1 benefit in acute stroke (within 4.5 hours). But for more than 4.5 hours cases (if they fail to qualify for clot retrievers within 12 hours), autologous Intracarotid/Intraarterial Platelet rich plasma (PRP) is used here to provide growth factors at the cyton level to maintain and restore the raw materials for the synaptic flow.

Aims/Study Design: PRP provides growth factors at the cyton level are the basis of the authors’ hypothesis to treat sub-acute stroke cases from 5th day to 21st day. Pilot study on 6 cases prospective study.

Materials and Methods: The human population included 6 sub-acute ischemic stroke patients from 5th to 21st post stroke day. The mean time for superfusion was 8 days post-stroke. Pre- and post PRP status was monitored by NIHSS, MRI-DWI and ALTENS.

Results: After 2 hours of PRP, the mean change in the NIHSS score was no change in NIHSS, ALTENS or MRI-DWI in LACS, PACS, TACS or POCS.

Conclusions: PRP alone via intracarotid do not cause improvement in neurological deficit in these 6 cases.

Keywords: Brain Infarcts; Intracarotid Platelet Rich Plasma; Nihss; Mri-Dwi; Altens

References

1. “Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke (NINDS) and rtPA Stroke study group”. The New England Journal of Medicine 333 (1995): 1817.
2. Werner Hacke., et al. “Association of outcome with early stroke treatment: Pooled analysis of ALANTIS, ECASS AND NINDS rt-PA stroke trials”. Lancet 33 (2004): 768-774.
3. MV , et al. “Hyperacute thrombolysis with IV rtPA of acute ischemic stroke : Efficacy and safety profile of 54 patients at a tertiary center in a developing country”. Neurology India 55 (2007): 46-49.
4. Gascou G., et al. “Stent Retrievers in Acute Ischemic Stroke: Complications and Failures during the Perioperative Period”. AJNR: American Journal of Neuroradiology 4 (2014): 734.
5. Zhang Y., et al. “Administration of human platelet-rich plasma reduces infarction volume and improves motor function in adult rats with focal ischemic stroke”. Brain Research 1594 (2015): 267-273.
6. Xue S., et al. “Stroke-induced damage on the blood-brain barrier”. Frontiers in Neurology 14 (2023): 1248970.
7. Intracarotid Sodium Nitroprusside on Fifth Post Ischemic Stroke Day in Middle Cerebral Artery Occlusion Rat Model. Vinod Kumar Tewari, Vivek Bhosale, Rakesh Shukla, Hari Kishan Das Gupta, Sheeba”. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH8 (2017): AF01-AF04.
8. Vinod Kumar., et al. “The 10,000-Fold Effect of Retrograde Neurotransmission, a New Concept for Stroke Revival: Use of Intracarotid Sodium Nitroprusside”. Journal of Evolution of Medical and Dental Sciences21 (2014): 5785-5803.
9. Dashore S., et al. “Preparation of Platelet-Rich Plasma: National IADVL PRP Taskforce Recommendations”. Indian Dermatology Online Journal 1 (2021): S12.
10. Bai W., et al. “The Clinical Efficacy of Double Plasma Molecular Absorption System Combined with Plasma Exchange in the Treatment of Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis”. Journal of Healthcare Engineering (2022): 3139929.
11. Zhang Y., et al. “Administration of human platelet-rich plasma reduces infarction volume and improves motor function in adult rats with focal ischemic stroke”. Brain Research 1594 (2015): 267-273.
12. Xue S., et al. “Stroke-induced damage on the blood-brain barrier”. Frontiers in Neurology 14 (2023): 1248970.
13. Blair P and Flaumenhaft “Platelet α-granules: Basic biology and clinical correlates”. Blood Reviews 23.4 (2009): 177.
14. Andrae J., et al. “Role of platelet-derived growth factors in physiology and medicine”. Genes and Development 10 (2008): 1276.

Citation

Citation: Seema Tewari., et al. “Intracarotid Platelet Rich Plasma In Sub-Acute Ischemic Stroke Cases (From 5th To 21st Post Stroke Day) - Pilot Study In 6 Cases Gives No Effect".Acta Scientific Neurology 8.10 (2025): 16-20.

Copyright

Copyright: © 2025 Seema Tewari., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.